{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:33:59Z","timestamp":1761863639380},"reference-count":22,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T00:00:00Z","timestamp":1481241600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T00:00:00Z","timestamp":1481241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1111\/ijcp.12916","type":"journal-article","created":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T07:02:44Z","timestamp":1481266964000},"page":"e12916","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The STOP-ACEi Trial - Apt timing for this long awaited randomised controlled trial - Validation of the syndrome of late-onset renal failure from angiotensin blockade (LORFFAB)?"],"prefix":"10.1155","volume":"71","author":[{"given":"Macaulay Amechi Chukwukadibia","family":"Onuigbo","sequence":"first","affiliation":[{"name":"Mayo Clinic College of Medicine; Rochester MN USA"},{"name":"Department of Nephrology; Mayo Clinic Health System; Eau Claire WI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2016,12,9]]},"reference":[{"key":"10.1111\/ijcp.12916-BIB0001|ijcp12916-cit-0001","first-page":"255","article-title":"Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease","volume":"31","author":"Bhandari","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/ijcp.12916-BIB0002|ijcp12916-cit-0002","first-page":"CR462","article-title":"Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experience","volume":"11","author":"Onuigbo","year":"2005","journal-title":"Med Sci Monit"},{"key":"10.1111\/ijcp.12916-BIB0003|ijcp12916-cit-0003","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/sj.ki.5001648","article-title":"Late-onset renal failure from RAAS blockade","volume":"70","author":"Onuigbo","year":"2006","journal-title":"Kidney Int"},{"key":"10.1111\/ijcp.12916-BIB0004|ijcp12916-cit-0004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/08860220701742161","article-title":"Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors","volume":"30","author":"Onuigbo","year":"2008","journal-title":"Ren Fail"},{"key":"10.1111\/ijcp.12916-BIB0005|ijcp12916-cit-0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11255-007-9299-2","article-title":"Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients","volume":"40","author":"Onuigbo","year":"2008","journal-title":"Int Urol Nephrol"},{"key":"10.1111\/ijcp.12916-BIB0006|ijcp12916-cit-0006","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/qjmed\/hcn142","article-title":"Reno-prevention vs. reno-protection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET-a call for more circumspection","volume":"102","author":"Onuigbo","year":"2009","journal-title":"QJM"},{"key":"10.1111\/ijcp.12916-BIB0007|ijcp12916-cit-0007","doi-asserted-by":"crossref","first-page":"c63","DOI":"10.1159\/000228536","article-title":"Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution","volume":"113","author":"Onuigbo","year":"2009","journal-title":"Nephron Clin Pract"},{"key":"10.1111\/ijcp.12916-BIB0008|ijcp12916-cit-0008","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/ndt\/gfp678","article-title":"The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Onuigbo","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/ijcp.12916-BIB0009|ijcp12916-cit-0009","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1742-1241.2010.02448.x","article-title":"Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far?","volume":"64","author":"Onuigbo","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12916-BIB0010|ijcp12916-cit-0010","doi-asserted-by":"crossref","first-page":"c407","DOI":"10.1159\/000324164","article-title":"Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients?","volume":"118","author":"Onuigbo","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1111\/ijcp.12916-BIB0011|ijcp12916-cit-0011","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/0886022X.2012.741644","article-title":"Renoprevention: a new concept for reengineering nephrology care-an economic impact and patient outcome analysis of two hypothetical patient management paradigms in the CCU","volume":"35","author":"Onuigbo","year":"2013","journal-title":"Ren Fail"},{"key":"10.1111\/ijcp.12916-BIB0012|ijcp12916-cit-0012","first-page":"75","volume-title":"ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics","author":"Onuigbo","year":"2013"},{"key":"10.1111\/ijcp.12916-BIB0013|ijcp12916-cit-0013","first-page":"127","volume-title":"ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics","volume":"1","author":"Onuigbo","year":"2013"},{"key":"10.1111\/ijcp.12916-BIB0014|ijcp12916-cit-0014","first-page":"104","volume-title":"Handbook Of Physiology: Section 7: The Endocrine System. Volume III: Endocrine Regulation of Water and Electrolyte Balance","author":"Ballerman","year":"2000"},{"key":"10.1111\/ijcp.12916-BIB0015|ijcp12916-cit-0015","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/qjmed\/77.1.997","article-title":"Angiotensin-converting enzyme inhibition and renovascular disease","volume":"77","author":"Raine","year":"1990","journal-title":"Q J Med"},{"key":"10.1111\/ijcp.12916-BIB0016|ijcp12916-cit-0016","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/ijcp.12916-BIB0017|ijcp12916-cit-0017","doi-asserted-by":"crossref","first-page":"c348","DOI":"10.1159\/000330289","article-title":"Stopping renin-angiotensin system inhibitors in chronic kidney disease: predictors of response","volume":"119","author":"Gon\u00e7alves","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1111\/ijcp.12916-BIB0018|ijcp12916-cit-0018","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/ijcp.12475","article-title":"A randomized clinical trial to determine the effect of angiotensin inhibitors reduction on creatinine clearance and haemoglobin in heart failure patients with chronic kidney disease and anaemia","volume":"68","author":"Pita-Fern\u00e1ndez","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12916-BIB0019|ijcp12916-cit-0019","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamainternmed.2013.12700","article-title":"Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia","volume":"174","author":"Hsu","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1111\/ijcp.12916-BIB0020|ijcp12916-cit-0020","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jacc.2013.10.050","article-title":"Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease","volume":"63","author":"Molnar","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/ijcp.12916-BIB0021|ijcp12916-cit-0021","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/ijcp.12916-BIB0022|ijcp12916-cit-0022","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12916","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ijcp.12916\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:09:57Z","timestamp":1643350197000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,9]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12916","archive":["Portico"],"relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12,9]]}}}